Advertisement
Screener

Polaryx Therapeutics, Inc. (PLYX) Increase (Decrease) in Accounts Payable

2.8 / 5 stars · 68/120 Roast Me

Polaryx Therapeutics, Inc. Increase (Decrease) in Accounts Payable

Polaryx Therapeutics, Inc. (PLYX) reported Increase (Decrease) in Accounts Payable of $213.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13

  • Polaryx Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$167.00K, a 262.14% decline year-over-year.
  • Polaryx Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $380.00K.
  • Polaryx Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-06-30 was $103.00K.
  • Polaryx Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-03-31 was -$17.00K.
  • Polaryx Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $398.00K.
  • Polaryx Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$401.00K.
Period endIncrease (Decrease) in Accounts Payable 3 monthIncrease (Decrease) in Accounts Payable 6 monthIncrease (Decrease) in Accounts Payable 12 month
2026-06-30-$167.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$213.00K
10-Q · filed 2026-08-13
2026-03-31$380.00K
10-Q · filed 2026-05-15
2025-12-31$398.00K
10-K · filed 2026-03-24
2025-06-30$103.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$86.00K
10-Q · filed 2026-08-13
2025-03-31-$17.00K
10-Q · filed 2026-05-15
2024-12-31-$401.00K
10-K · filed 2026-03-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Equillium, Inc. (EQ)United States$0.109B-11.27
ProMIS Neurosciences Inc. (PMN)$0.102B
GENELUX Corp (GNLX)United States$0.110B-3.83
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Anixa Biosciences Inc (ANIX)United States$0.096B